Trial Profile
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 14 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2024.
- 14 Feb 2022 Planned primary completion date changed from 1 Jul 2021 to 1 Dec 2023.
- 03 Mar 2021 Status changed from recruiting to active, no longer recruiting.